ファイル | |
言語 |
英語
|
著者 |
Enomoto, Hiroyuki
Biomedicine, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan
Ishida, Mitsuhiro
Clinical Research Development, Shionogi & Co. Ltd, Osaka, Japan
Tsuji, Toshinaga
Medical Affairs Department, Shionogi & Co. Ltd, Osaka, Japan
Ochiai, Toshimitsu
Biostatistics Center, Shionogi & Co. Ltd, Osaka, Japan
Konno, Shinichi
Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima, Japan
|
内容記述(抄録等) | Purpose: To assess long-term safety, tolerability, and efficacy of duloxetine in Japanese patients with chronic knee pain due to osteoarthritis.
Methods: In this open-label extension study (NCT02335346), Japanese patients with kneeosteoarthritis and pain (Brief Pain Inventory [BPI] – Severity average pain score ≥4 at start of randomized trial) who had previously received duloxetine 60 mg/day or placebo for 14 weeks in a double-blind randomized trial entered the extension and received duloxetine 60 mg/day for 48 weeks. The primary outcome was safety/tolerability, secondary outcomes were change in BPI-Severity (BPI-S) average pain, BPI-Interference (BPI-I), Patient Global Impression-Improvement (PGI-I), Clinical Global Impression-Improvement (CGI-I), 36-item Short-Form Health Survey (SF36), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and exploratory outcomes were knee range of motion (efficacy outcome) and Kellgren–Lawrence grade (safety outcome). Results: Of 323 patients who completed the randomized trial, 93 (50 placebo, 43 duloxetine) entered the extension. Most patients (85, 91.4%) experienced an adverse event, most commonly constipation, nasopharyngitis, somnolence, and dry mouth (≥10% of patients). There were eight serious adverse events in seven patients and no deaths. No obvious duloxetine-related changes were observed in laboratory tests, vital signs, or electrocardiograms. The change from baseline in BPI-S average pain score was significant throughout the extension. Significant reductions in BPI-I, PGI-I, CGI-I, WOMAC, and SF36 scores were also maintained through 52 weeks. There were no substantial changes in range of motion or Kellgren–Lawrence grade. Conclusion: In Japanese patients with chronic knee pain due to osteoarthritis, long-term treatment with duloxetine was well tolerated and associated with sustained improvements in pain and health-related quality of life without radiographic deterioration. |
主題 | analgesics
chronic pain due to knee osteoarthritis
duloxetine
quality of life
Western Ontario and McMaster Universities Osteoarthritis Index
|
掲載誌名 |
Journal of Pain Research
|
巻 | 11
|
開始ページ | 1391
|
終了ページ | 1403
|
ISSN | 1178-7090
|
発行日 | 2018
|
DOI | |
出版者 | Dove Press Ltd
|
資料タイプ |
学術雑誌論文
|
ファイル形式 |
PDF
|
権利関係 | The authors would like to thank all clinical investigators and patients for their participation in the study. Medical writing assistance was provided by Rebecca Lew, PhD, CMPP and Hiroko Ebina, BPharm, Ph, MBA of ProScribe - Envision Pharma Group - and was funded by Shionogi & Co. Ltd. and Eli Lilly Japan K.K. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3). This study was conducted by Shionogi and funded by Eli Lilly Japan and Shionogi, manufacturers and licensees of Cymbalta (duloxetine) in Japan.
|
業績ID | e35185
|
部局 |
医学部
|